NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 181 filers reported holding NOVOCURE LTD in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $4,436,000 | +34.2% | 20,000 | -20.0% | 0.50% | +8.8% |
| Q1 2021 | $3,305,000 | -6.8% | 25,000 | +22.0% | 0.46% | -18.2% |
| Q4 2020 | $3,547,000 | -10.9% | 20,500 | -42.7% | 0.56% | -27.6% |
| Q3 2020 | $3,979,000 | +57.4% | 35,750 | -52.6% | 0.77% | +171.8% |
| Q4 2018 | $2,528,000 | -66.0% | 75,500 | -46.7% | 0.28% | -48.0% |
| Q3 2018 | $7,428,000 | +3.2% | 141,750 | -38.4% | 0.55% | +2.8% |
| Q2 2018 | $7,199,000 | +15.7% | 230,000 | -19.4% | 0.53% | +8.1% |
| Q1 2018 | $6,224,000 | +12.7% | 285,500 | +4.4% | 0.49% | +21.2% |
| Q4 2017 | $5,525,000 | +32.2% | 273,500 | +29.9% | 0.40% | +43.6% |
| Q3 2017 | $4,178,000 | – | 210,500 | – | 0.28% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |